Using low doses of carbon monoxide to treat lung injuries caused by viruses
Official title: Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury
Funded at Hillhurst Biopharmaceuticals, INC. · NIH-10682510 · Data updated 2026-11-12
This study is looking at whether taking a small amount of carbon monoxide by mouth can help people with lung injuries from viral infections like COVID-19 by reducing inflammation and helping their bodies fight off the virus more effectively.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hillhurst Biopharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Montrose, United States) |
| Project start | August 11, 2022 |
| Project end | July 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $299,894 |
| NIH project number | 5R41AI164948-02 |
| Project ID | NIH-10682510 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients experiencing pulmonary injuries due to viral infections, particularly those affected by COVID-19.
✕Less likely to help
Patients with lung injuries not caused by viral infections or those who cannot tolerate carbon monoxide therapy may not benefit from this research.
What this research studies
This research investigates the use of low-dose oral carbon monoxide as a potential treatment for lung injuries resulting from viral infections, such as COVID-19. The approach focuses on reducing inflammation and enhancing the body's ability to clear viruses from the lungs. By utilizing a method that avoids the risks associated with inhaled carbon monoxide, the study aims to provide a safer and more effective therapeutic option for patients suffering from pulmonary damage. The research builds on previous successful studies that have shown the safety and efficacy of carbon monoxide in treating lung conditions.
Why it matters
Potential benefit: If successful, this research could offer a novel and safer treatment option for patients with lung injuries caused by viral infections.
How similar studies have gone: Previous studies have demonstrated the safety and efficacy of carbon monoxide in treating lung injuries, indicating a promising potential for this novel approach.
Where this research is happening
-
Hillhurst Biopharmaceuticals, INC.
Montrose, United States Active
Researchers
- Principal investigator: Gomperts, Edward — Hillhurst Biopharmaceuticals, INC.
- Study coordinator: Gomperts, Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.